Results 291 to 300 of about 3,018,484 (379)

Off-Label and Unlicensed Drug Use in Neonatology: Reality in a Portuguese University Hospital

, 2015
Joana Silva, Filipa Flôr-de-Lima, Henrique Soares, Hercília Guimarães   +3 more
openalex   +2 more sources

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Correction to: Low to moderate-dose off-label use of second-generation antipsychotics seems to be safe in the light of cardiac adverse effects in child psychiatric patients. [PDF]

Eur J Pediatr
Kakko K, Salmelin R, Puura K, Poutanen T.   +3 more
europepmc   +1 more source

The off-label use of drugs for parenteral nutrition as a solvent of substances slightly soluble in water in pharmacological research

, 2018
А. В. Самородов, Александр Ураков, И Г Мустафин, FelixKh Kamilov, Ф. А. Халиуллин   +4 more
openalex   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Low to moderate-dose off-label use of second-generation antipsychotics seems to be safe in the light of cardiac adverse effects in child psychiatric patients. [PDF]

Eur J Pediatr
Kakko K, Salmelin R, Puura K, Poutanen T.   +3 more
europepmc   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

Off-label use of the pipeline embolization device for reconstruction of the extracranial internal carotid artery. [PDF]

Surg Neurol Int
Jee E, Ansari J, Kandregula S, Chokhawala H, Sharma P, Guthikonda B, Cuellar Saenz H, Savardekar A.   +7 more
europepmc   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Off label use of a 7Fr endo-biliary forceps system for endovascular inferior vena cava biopsy. [PDF]

CVIR Endovasc
Grigoriadis S, Spiliopoulos S, Korogiannos A, Palialexis K, Filippiadis D, Kelekis N.   +5 more
europepmc   +1 more source